Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tabalumab plus bortezomib and dexamethasone in previously treated multiple myeloma (Phase 2/3, double-blind, placebo-controlled)
KCT0001110Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of tabalumab in multiple myeloma (MM), sponsored by Eli Lilly and Company. Started Jul 2012; status: active, not recruiting.
02
Drugs
tabalumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on KCT0001110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001110.